Biotech · Public company · Coral Gables, FL, US

Relmada Therapeutics, Inc.

Ticker RLMD · SEC CIK 0001553643

Track this companyFree. Adds Relmada Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials40 recruiting or active

Pipeline programs2From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline2

REL-1017Phase 3 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
REL-1017Phase 2 · Depressive Disorder, MajorClinicalTrials.gov · fetched Nov 12, 2026

A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)PHASE3 · COMPLETED · started Jun 2, 2021ClinicalTrials.gov NCT05081167 · fetched Nov 12, 2026
Safety of REL-1017 for Major Depressive DisorderPHASE3 · COMPLETED · started Apr 1, 2021ClinicalTrials.gov NCT04855760 · fetched Nov 12, 2026
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)PHASE3 · COMPLETED · started Jan 8, 2021ClinicalTrials.gov NCT04688164 · fetched Nov 12, 2026
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDDPHASE2 · COMPLETED · started May 11, 2018ClinicalTrials.gov NCT03051256 · fetched Nov 12, 2026